Health Care [ 2/12 ] | Biotechnology [ 14/74 ]
NASDAQ | Common Stock
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.
Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.
It has a license agreement with Meros.
The company was incorporated in 2017 and is headquartered in Oakville, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 31, 25 | -0.09 Increased by 0.00% | -0.12 Increased by +22.88% |
| Nov 12, 24 | -0.18 Decreased by -100.00% | -0.08 Decreased by -125.00% |
| Aug 12, 24 | -0.10 Increased by +16.67% | -0.13 Increased by +23.08% |
| Apr 1, 24 | -0.12 Decreased by -9.09% | -0.12 |
| Mar 28, 24 | -0.09 Increased by +25.00% | -0.09 |
| Nov 14, 23 | -0.09 Increased by +30.77% | -0.12 Increased by +25.00% |
| Aug 10, 23 | -0.12 Decreased by -20.00% | -0.12 |
| May 15, 23 | -0.11 Increased by +21.43% | -0.15 Increased by +26.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by N/A% | -8.18 M Decreased by -37.91% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -12.73 M Decreased by -70.35% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -6.59 M Increased by +7.03% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -9.18 M Decreased by -22.15% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -5.93 M Increased by +25.61% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -7.47 M Decreased by -15.14% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -7.09 M Increased by +20.83% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -7.52 M Decreased by -20.10% | Decreased by N/A% Decreased by N/A% |